| Year |
Citation |
Score |
| 2022 |
Berrou J, Dupont M, Djamai H, Adicéam E, Parietti V, Kaci A, Clappier E, Cayuela JM, Baruchel A, Paublant F, Prudent R, Ghysdael J, Gardin C, Dombret H, Braun T. Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive () Acute Lymphoblastic Leukemia (ALL). Journal of Clinical Medicine. 11. PMID 36431240 DOI: 10.3390/jcm11226761 |
0.381 |
|
| 2022 |
Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, ... ... Braun T, et al. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia. PMID 35474100 DOI: 10.1038/s41375-022-01573-6 |
0.324 |
|
| 2021 |
Djamai H, Berrou J, Dupont M, Coudé MM, Delord M, Clappier E, Marceau-Renaut A, Kaci A, Raffoux E, Itzykson R, Berthier C, Wu HC, Hleihel R, Bazarbachi A, de Thé H, ... ... Braun T, et al. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines. 9. PMID 34829934 DOI: 10.3390/biomedicines9111704 |
0.368 |
|
| 2021 |
Sevin M, Debeurme F, Laplane L, Badel S, Morabito M, Newman HL, Torres-Martin M, Yang Q, Badaoui B, Wagner-Ballon O, Saada V, Selimoglu-Buet D, Kraus-Berthier L, Banquet S, Derreal A, ... ... Braun T, et al. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood. PMID 33690800 DOI: 10.1182/blood.2020008729 |
0.453 |
|
| 2020 |
Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Leukemia Research. 100: 106490. PMID 33373830 DOI: 10.1016/j.leukres.2020.106490 |
0.361 |
|
| 2020 |
Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances. 4: 1942-1949. PMID 32380535 DOI: 10.1182/Bloodadvances.2019001349 |
0.374 |
|
| 2020 |
Habault J, Kaci A, Pasquereau-Kotula E, Fraser C, Chomienne C, Dombret H, Braun T, Pla M, Poyet JL. Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53. Oncoimmunology. 9: 1728871. PMID 32158621 DOI: 10.1080/2162402X.2020.1728871 |
0.345 |
|
| 2020 |
Kim R, Boissel N, Touzart A, Leguay T, Thonier F, Thomas X, Raffoux E, Huguet F, Villarese P, Fourrage C, Passini L, Hunault M, Lepretre S, Chevallier P, Braun T, et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia. PMID 31992840 DOI: 10.1038/S41375-019-0685-4 |
0.321 |
|
| 2019 |
Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, ... ... Braun T, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Advances. 3: 4238-4251. PMID 31869411 DOI: 10.1182/Bloodadvances.2019000647 |
0.394 |
|
| 2019 |
Massé A, Roulin L, Pasanisi J, Penneroux J, Gachet S, Delord M, Ali A, Alberdi A, Berrou J, Passet M, Hernandez L, Quentin S, Gardin C, Raffoux E, Adès L, ... Braun T, et al. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias. Leukemia Research. 87: 106269. PMID 31751766 DOI: 10.1016/J.Leukres.2019.106269 |
0.401 |
|
| 2019 |
Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, et al. Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements. Blood. PMID 31434701 DOI: 10.1182/Blood.2019001244 |
0.313 |
|
| 2019 |
Kaci A, Adiceam E, Dupont M, Garrido M, Berrou J, Djamai H, Baruchel A, Burbridge M, Gardin C, Dombret H, Braun T. Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL) Blood. 134: 2631-2631. DOI: 10.1182/Blood-2019-125641 |
0.434 |
|
| 2019 |
Braun T, Berrou J, Djamai H, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H. Abstract 341: Synergy of FLT3 inhibitors and a small molecule inhibitor of LIM kinase1/2 in FLT3-ITD positive acute myeloblastic leukemia (AML) Cancer Research. 79: 341-341. DOI: 10.1158/1538-7445.Sabcs18-341 |
0.459 |
|
| 2018 |
Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P. A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM). Haematologica. PMID 30381302 DOI: 10.3324/Haematol.2018.203885 |
0.344 |
|
| 2018 |
Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, et al. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research. 71: 67-74. PMID 30025278 DOI: 10.1016/J.Leukres.2018.05.007 |
0.391 |
|
| 2018 |
Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, ... ... Braun T, et al. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. British Journal of Haematology. PMID 30004110 DOI: 10.1111/Bjh.15490 |
0.341 |
|
| 2018 |
Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. Ebiomedicine. PMID 29728305 DOI: 10.1016/J.Ebiom.2018.04.018 |
0.354 |
|
| 2018 |
Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, et al. Nationwide Survey on the Use of Horse Antithymocyte Globulins (ATGAM) in Patients with Acquired Aplastic Anemia: A Report on Behalf of the French Reference Center for Aplastic Anemia. American Journal of Hematology. PMID 29377260 DOI: 10.1002/Ajh.25050 |
0.324 |
|
| 2018 |
Vidal V, Hamri L, Marceau-Renaut A, Fontbrune FSD, Eclache V, Osman N, Papoular B, Lusina D, Brechignac S, Latour RPD, Preudhomme C, Gardin C, Braun T. A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML) Blood. 132: 4007-4007. DOI: 10.1182/Blood-2018-99-117237 |
0.344 |
|
| 2018 |
Braun T, Berrou J, Prudent R, Djamai H, Dupont M, Kaci A, Adiceam E, Paublant F, Baruchel A, Ghysdael J, Gardin C, Dombret H. Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blood. 132: 2705-2705. DOI: 10.1182/Blood-2018-99-115933 |
0.431 |
|
| 2018 |
Ades L, Guerci A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Bouabdallah K, Braun T, Beyne-Rauzy O, et al. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial Blood. 132: 467-467. DOI: 10.1182/Blood-2018-99-111756 |
0.348 |
|
| 2018 |
Itzykson R, Fournier E, Braun T, Berthon C, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Duployez N, Micol J, Ades L, Marolleau J, Malfuson JV, Gastaud L, Raffoux E, et al. Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial Blood. 132: 993-993. DOI: 10.1182/Blood-2018-99-111144 |
0.341 |
|
| 2018 |
Braun T, Coudé M, Berrou J, Djamai H, Dupont M, Kaci A, Delord M, Itzykson R, Raffoux E, Berthier C, Baruchel A, Gardin C, Dombret H. Abstract 803: Bromodomain and extra-terminal BET inhibitors induce TP53 independent apoptosis, maturation and oncoprotein degradation in NPM1 mutated acute myeloid leukemia Cancer Research. 78: 803-803. DOI: 10.1158/1538-7445.Am2018-803 |
0.473 |
|
| 2017 |
Braun T, Gardin C. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). Expert Opinion On Investigational Drugs. PMID 28541716 DOI: 10.1080/13543784.2017.1335711 |
0.359 |
|
| 2017 |
Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. PMID 28514758 DOI: 10.18632/Oncotarget.17482 |
0.412 |
|
| 2017 |
Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, ... ... Braun T, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 185-193. PMID 28056203 DOI: 10.1200/Jco.2016.67.1875 |
0.391 |
|
| 2017 |
Itzykson R, Lambert J, Barbieri D, Gruson B, Thepot S, Braun T, Vey N, Delaunay J, Legros L, Lejeune J, Sapena R, Droin N, Porteu F, Solary E, Fenaux P. A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia Blood. 130: 4266-4266. DOI: 10.1182/Blood.V130.Suppl_1.4266.4266 |
0.343 |
|
| 2017 |
Duchmann M, Yalniz F, Sanna A, Sallman DA, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Ades L, Fontenay M, Rampal RK, Padron E, Droin N, et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients Blood. 130: 159-159. DOI: 10.1182/Blood.V130.Suppl_1.159.159 |
0.347 |
|
| 2016 |
Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies. British Journal of Haematology. PMID 27977052 DOI: 10.1111/Bjh.14427 |
0.302 |
|
| 2016 |
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. The New England Journal of Medicine. 375: 1044-1053. PMID 27626518 DOI: 10.1056/Nejmoa1605085 |
0.319 |
|
| 2016 |
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, et al. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget. 7: 85573-85583. PMID 27458168 DOI: 10.18632/Oncotarget.10764 |
0.367 |
|
| 2016 |
Fraison JB, Mekinian A, Grignano E, Kahn JE, Arlet JB, Decaux O, Denis G, Buchdahl AL, Omouri M, Maigne G, Aouba A, Leon N, Berthier S, Liozon E, Park S, ... ... Braun T, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research. 43: 13-17. PMID 26922775 DOI: 10.1016/J.Leukres.2016.02.005 |
0.317 |
|
| 2016 |
Michallet M, Sobh M, Deloire A, Raffoux E, Botton Sd, Caillot D, Reman O, Girault S, Berthon C, Huguet F, Lepretre S, Leguay T, Castaigne S, Royer B, Pautas C, ... ... Braun T, et al. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group Blood. 128: 3696-3696. DOI: 10.1182/Blood.V128.22.3696.3696 |
0.301 |
|
| 2015 |
Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 20: 1666-7. PMID 26400497 DOI: 10.1007/S10495-015-1154-9 |
0.798 |
|
| 2015 |
Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 6: 17698-712. PMID 25989842 DOI: 10.18632/Oncotarget.4131 |
0.422 |
|
| 2015 |
Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 125: 3618-26. PMID 25852055 DOI: 10.1182/Blood-2015-01-620781 |
0.321 |
|
| 2015 |
Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, et al. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. Cancer. 121: 2393-9. PMID 25845577 DOI: 10.1002/Cncr.29389 |
0.317 |
|
| 2015 |
Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research. 39: 501-4. PMID 25735917 DOI: 10.1016/J.Leukres.2015.02.004 |
0.379 |
|
| 2015 |
Poret E, Vidal C, Desbrosses Y, Delettre FA, Pagadoy M, Pugin A, Benazet L, Leroux F, Robert E, Binda D, Biichle S, Roggy A, Philippe L, Gruson B, Gac A, ... ... Braun T, et al. How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network Blood. 126: 456-456. DOI: 10.1182/Blood.V126.23.456.456 |
0.367 |
|
| 2015 |
Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N. A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study Blood. 126: 2900-2900. DOI: 10.1182/Blood.V126.23.2900.2900 |
0.349 |
|
| 2015 |
Duchmann M, Braun T, Platzbecker U, Adès L, Sébert M, Dreyfus F, Park S, Vey N, Rauzy OB, Botton SD, Micol J, Berthon C, Guieze R, Bastie JM, Solary É, et al. Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA) Blood. 126: 2893-2893. DOI: 10.1182/Blood.V126.23.2893.2893 |
0.348 |
|
| 2015 |
Bigenwald C, Harel S, Chevillon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Lionel A, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P. Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related Blood. 126: 2886-2886. DOI: 10.1182/Blood.V126.23.2886.2886 |
0.351 |
|
| 2015 |
Sebert M, Stamatoullas A, Braun T, Delaunay J, de Renzis B, Jeddi R, Meddeb B, Hunault Berger M, Samey B, Chermat F, Chevret S, Chaffaut C, Fenaux P, Ades L. Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM) Blood. 126: 2884-2884. DOI: 10.1182/Blood.V126.23.2884.2884 |
0.359 |
|
| 2015 |
Drevon L, Marceau A, Eclache V, Raynaud SD, Richez V, Berkaoui I, Maarek O, Cuccuini W, Lusina D, Berthon C, Dimicoli-Salazar S, Bidet A, Vial J, Park S, Stamatoullas A, ... ... Braun T, et al. MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM Blood. 126: 2881-2881. DOI: 10.1182/Blood.V126.23.2881.2881 |
0.35 |
|
| 2015 |
Duchmann M, Braun T, Kosmider O, Renneville A, Platzbecker U, Ades L, Sebert M, Dreyfus F, Park S, Vey N, Beyne Rauzy O, De Botton S, Micol J, Guieze R, Bastie JM, et al. A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM Blood. 126: 2872-2872. DOI: 10.1182/Blood.V126.23.2872.2872 |
0.35 |
|
| 2015 |
Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Samey B, Desseaux K, Chevret S, Fenaux P. A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM) Blood. 126: 2869-2869. DOI: 10.1182/Blood.V126.23.2869.2869 |
0.347 |
|
| 2015 |
Roulin L, Ali A, Masse A, Coudé M, Bluteau D, Braun T, Berrou J, Bluteau O, Delord M, Riveiro ME, Herait PE, Soulier J, Baruchel A, Gardin C, Dombret H, et al. Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells Blood. 126: 2588-2588. DOI: 10.1182/Blood.V126.23.2588.2588 |
0.405 |
|
| 2015 |
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Braun T, Marolleau J, Chalandon Y, et al. Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study Blood. 126: 1-1. DOI: 10.1182/Blood.V126.23.1.1 |
0.357 |
|
| 2015 |
Braun T, Debache A, Roudot H, Lusina D, Thépot S, Eclache V, Martin A, Soret J, Bréchignac S, Kelaidi C, Adès L, Fenaux P, Gardin C. 205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U) Leukemia Research. 39: S102. DOI: 10.1016/S0145-2126(15)30206-X |
0.3 |
|
| 2015 |
Ades L, Renneville A, Marceau A, Sebert M, Braun T, Nibourel O, Preudhomme C, Fenaux P. 142 Molecular Prognostic Factors In Higher Risk Mds Receiving First Line Azacytidine (Aza) Leukemia Research. 39. DOI: 10.1016/S0145-2126(15)30143-0 |
0.311 |
|
| 2015 |
Cluzeau T, Vidal V, Ginet C, Karsenti J, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga A, Dombret H, Rorhlich P, Ades L, Chomienne C, et al. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML Leukemia Research. 39: S23. DOI: 10.1016/S0145-2126(15)30051-5 |
0.352 |
|
| 2014 |
Mirouse A, Virone A, Gobert D, Soussan M, Braun T, Ziol M, Gardin C, Fenaux P, Mekinian A, Fain O. Aseptic muscular abscesses associated with myelodysplastic syndrome. European Journal of Dermatology : Ejd. 24: 696-7. PMID 25333797 DOI: 10.1684/Ejd.2014.2435 |
0.315 |
|
| 2014 |
Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, et al. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood. 124: 1312-9. PMID 25006122 DOI: 10.1182/Blood-2014-01-549212 |
0.357 |
|
| 2014 |
Mekinian A, Braun T, Decaux O, Falgarone G, Toussirot E, Raffray L, Omouri M, Gombert B, De Wazieres B, Buchdaul AL, Ziza JM, Launay D, Denis G, Madaule S, Rose C, et al. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine. 93: 1-10. PMID 24378738 DOI: 10.1097/Md.0000000000000011 |
0.319 |
|
| 2014 |
Coudé M, Braun T, Berrou J, Dupont M, Itzykson R, Masse A, Raffoux E, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C. Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 in a Panel of Human Acute Leukemia Cell Lines Blood. 124: 5957-5957. DOI: 10.1182/Blood.V124.21.5957.5957 |
0.382 |
|
| 2014 |
Braun T, Debache A, Roudot H, Lusina D, Thépot S, Eclache V, Martin A, Soret J, Harel S, Bréchignac S, Kelaidi C, Adès L, Fenaux P, Gardin C. Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report Blood. 124: 5610-5610. DOI: 10.1182/Blood.V124.21.5610.5610 |
0.35 |
|
| 2014 |
Vidal V, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Dombret H, Rohrlich P, Ades L, Chomienne C, Fenaux P, et al. BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 124: 3261-3261. DOI: 10.1182/Blood.V124.21.3261.3261 |
0.412 |
|
| 2014 |
Mekinian A, Grignano E, Braun T, Olivier D, Eric L, Nathalie C, jean Emmanuel K, Hamidou M, Puechal X, Park S, Toussirot E, Falgarone G, Launay D, Nathalie M, Trouiller S, et al. Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study Blood. 124: 3254-3254. DOI: 10.1182/Blood.V124.21.3254.3254 |
0.353 |
|
| 2014 |
Kelaidi C, Braun T, Lazarian G, Soret J, Cereja S, Eclache V, Lusina D, Adès L, Martin A, Fenaux P, Gardin C. Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA) Blood. 124: 1921-1921. DOI: 10.1182/Blood.V124.21.1921.1921 |
0.375 |
|
| 2013 |
Braun T, Fenaux P. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Practice & Research. Clinical Haematology. 26: 327-36. PMID 24507810 DOI: 10.1016/J.Beha.2013.09.003 |
0.351 |
|
| 2013 |
Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, Caillot D, Cornillon J, Dimicoli S, Etienne A, Galicier L, Garnier A, Girault S, Hunault-Berger M, Marolleau JP, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. British Journal of Haematology. 162: 489-97. PMID 23772757 DOI: 10.1111/Bjh.12415 |
0.366 |
|
| 2013 |
Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Lambert C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Annals of Hematology. 92: 621-31. PMID 23358617 DOI: 10.1007/S00277-013-1686-4 |
0.331 |
|
| 2013 |
Sebert M, Braun T, Gardin C, Martin A, Brechignac S, Harel S, Fenaux P, Ades L. Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study Blood. 122: 1539-1539. DOI: 10.1182/Blood.V122.21.1539.1539 |
0.39 |
|
| 2013 |
Braun T, Cherait A, Rigal M, Bréchignac S, Thépot S, Gardin C, Adès L, Fenaux P. P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70330-8 |
0.309 |
|
| 2013 |
Braun T, Raffoux E, Prebet T, Stamatoullas A, Bréchignac S, Dreyfus F, Samey B, Adès L, Vey N, Dombret H, Fenaux P, Gardin C. P-281 Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA) Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70328-X |
0.36 |
|
| 2013 |
Braun T, Miyara M, Itzykson R, Renneville A, Kosmider O, Gardin C, Solary E, Gorochov G, Fenaux P, Adès L. P-245 Effector CD4+CD45RA-CD25brightFoxp3bright regulatory T cells (eTregs) are significantly increased in chronic myelomonocytic leukemia (CMML) with TET2 mutations Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70292-3 |
0.346 |
|
| 2012 |
Natarajan-Amé S, Park S, Ades L, Vey N, Guerci-Bresler A, Cahn JY, Etienne G, Bordessoule D, Ravoet C, Legros L, Cheze S, Stamatoullas A, Berger E, Schmidt A, Charbonnier A, ... ... Braun T, et al. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. British Journal of Haematology. 158: 232-7. PMID 22571447 DOI: 10.1111/J.1365-2141.2012.09153.X |
0.415 |
|
| 2012 |
Prebet T, Braun T, Beyne-Rauzy O, Wattel E, Dreyfus F, Stamatoulas A, Ame S, Delaunay J, Raffoux E, Chermat F, Fenaux P, Vey N. Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure Blood. 120: 3825-3825. DOI: 10.1182/Blood.V120.21.3825.3825 |
0.308 |
|
| 2012 |
Vidal V, Sebert M, Thepot S, Braun T, Gardin C, Brechignac S, Fenaux P, Ades L. Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients Blood. 120: 3812-3812. DOI: 10.1182/Blood.V120.21.3812.3812 |
0.334 |
|
| 2012 |
Cluzeau T, Dhedin N, Huguet F, Raffoux E, Maury S, Mannone L, Escoffre-Barbe M, Le Calloch R, Delannoy A, Turlure P, Braun T, Vey N, Baruchel A, Dombret H, Boissel N. Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT) Blood. 120: 3561-3561. DOI: 10.1182/Blood.V120.21.3561.3561 |
0.31 |
|
| 2012 |
Braun T, Miyara M, Itzykson R, Renneville A, Kosmider O, Gardin C, Solary E, Gorochov G, Fenaux P, Ades L. Effector CD4+CD45RA−CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status. Blood. 120: 2808-2808. DOI: 10.1182/Blood.V120.21.2808.2808 |
0.364 |
|
| 2012 |
Sebert M, Vidal V, Eclache V, Thepot S, Braun T, Gardin C, Fenaux P, Ades L. Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA). Blood. 120: 2807-2807. DOI: 10.1182/Blood.V120.21.2807.2807 |
0.343 |
|
| 2012 |
Ades L, Renzis Bd, Jeddi R, Delaunay J, Braun T, Berger MH, Stamatoullas A, Sanhes L, Samey B, Chermat F, Meddeb B, Fenaux P. Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies Blood. 120: 1720-1720. DOI: 10.1182/Blood.V120.21.1720.1720 |
0.359 |
|
| 2011 |
Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, Royer B, Joly B, Vekhoff A, Lafon I, Sanhes L, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 118: 3824-31. PMID 21828134 DOI: 10.1182/Blood-2011-05-352039 |
0.344 |
|
| 2011 |
Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, et al. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leukemia Research. 35: 863-7. PMID 21396711 DOI: 10.1016/J.Leukres.2011.02.008 |
0.309 |
|
| 2011 |
Fain O, Braun T, Stirnemann J, Fenaux P. Manifestations systémiques et auto-immunes des syndromes myélodysplasiques Revue De MéDecine Interne. 32: 552-559. PMID 20850913 DOI: 10.1016/J.Revmed.2010.08.005 |
0.324 |
|
| 2011 |
Braun T, Raffoux E, Prebet T, Brechignac S, Stamatoullas A, Dreyfus F, Hebibi Z, Ades L, Vey N, Dombret H, Fenaux P, Gardin C. Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325) Blood. 118: 609-609. DOI: 10.1182/Blood.V118.21.609.609 |
0.329 |
|
| 2011 |
Sibon D, Berceanu A, Ghez D, Foissac F, Kammoun L, Braun T, Caillot D, Ojeda-Uribe M, Guieze R, Berthon C, Sanhes L, Gruson B, Bouscary D, Recher C, Stalnikiewicz L, et al. Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience Blood. 118: 2623-2623. DOI: 10.1182/Blood.V118.21.2623.2623 |
0.339 |
|
| 2011 |
Recher C, Thomas X, Tavernier E, Lioure B, Pautas C, Perrot A, Braun T, Cluzeau T, Malfuson J, Tamburini J, Berthon C, Magda A, Himberlin C, Botton Sd, Randriamalala E, et al. Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse Blood. 118: 2603-2603. DOI: 10.1182/Blood.V118.21.2603.2603 |
0.369 |
|
| 2010 |
Prebet T, Braun T, Rauzy OB, Dreyfus F, Stamatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Salanoubat C, Mathieu I, Chermat F, Ades L, Fenaux P, Vey N. A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study Blood. 116: 4003-4003. DOI: 10.1182/Blood.V116.21.4003.4003 |
0.306 |
|
| 2010 |
Droin N, Itzykson R, Rameau P, Morabito M, Braun T, Louache F, Zhang Y, Botton SD, Cordonnier C, Quesnel B, Fenaux P, Vainchenker W, Solary E. Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML Blood. 116: 3997-3997. DOI: 10.1182/Blood.V116.21.3997.3997 |
0.337 |
|
| 2009 |
Kelaidi C, Beyne-Rauzy O, Braun T, Cougoul P, Ades L, Pillard F, Lamberto C, Jernival T, Mortera E, Guerci A, Choufi B, Stamatoullas A, Slama B, Renzis BD, Ame S, et al. High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study. Blood. 114: 3812-3812. DOI: 10.1182/Blood.V114.22.3812.3812 |
0.322 |
|
| 2008 |
Grosjean-Raillard J, Tailler M, Adès L, Perfettini JL, Fabre C, Braun T, De Botton S, Fenaux P, Kroemer G. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 28: 1099-109. PMID 19079347 DOI: 10.1038/Onc.2008.457 |
0.784 |
|
| 2008 |
Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 13: 1148-61. PMID 18670883 DOI: 10.1007/s10495-008-0243-4 |
0.801 |
|
| 2008 |
Braun T, Fenaux P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology. 141: 576-86. PMID 18410457 DOI: 10.1111/J.1365-2141.2008.07099.X |
0.395 |
|
| 2008 |
Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood. 111: 2170-80. PMID 17925489 DOI: 10.1182/Blood-2007-07-100362 |
0.792 |
|
| 2007 |
Braun T, Carvalho G, Grosjean J, Ades L, Fabre C, Boehrer S, Debili N, Fenaux P, Kroemer G. Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation. Apoptosis : An International Journal On Programmed Cell Death. 12: 1101-8. PMID 17245643 DOI: 10.1007/S10495-006-0030-Z |
0.717 |
|
| 2007 |
Fabre C, Carvalho G, Tasdemir E, Braun T, Adès L, Grosjean J, Boehrer S, Métivier D, Souquère S, Pierron G, Fenaux P, Kroemer G. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 26: 4071-83. PMID 17213804 DOI: 10.1038/Sj.Onc.1210187 |
0.786 |
|
| 2007 |
Carvalho G, Fabre C, Braun T, Grosjean J, Ades L, Agou F, Tasdemir E, Boehrer S, Israel A, Véron M, Fenaux P, Kroemer G. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 26: 2299-307. PMID 17043643 DOI: 10.1038/Sj.Onc.1210043 |
0.785 |
|
| 2007 |
Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G. The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML. Blood. 110: 399-399. DOI: 10.1182/Blood.V110.11.399.399 |
0.792 |
|
| 2007 |
Boehrer S, Ades L, Galluzzi L, Olaussen K, Braun T, Grosjean J, Fabre C, de Botton S, Fenaux P, Kroemer G. Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways. Blood. 110: 2438-2438. DOI: 10.1182/Blood.V110.11.2438.2438 |
0.789 |
|
| 2007 |
Boehrer S, Adès L, Braun T, Grosjean J, Fabre C, Fenaux P, Kroemer G. P057 Abrogation of the DNA-damage response in AML versus MDS cell lines Leukemia Research. 31: S71. DOI: 10.1016/S0145-2126(07)70127-3 |
0.706 |
|
| 2007 |
Boehrer S, Adàs L, Braun T, Galluzzi L, Grosjean J, Fabre C, de Botton S, Gardin C, Fenaux P, Kroemer G. P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML Leukemia Research. 31: S62. DOI: 10.1016/S0145-2126(07)70109-1 |
0.735 |
|
| 2006 |
Coquelle A, Mouhamad S, Pequignot MO, Braun T, Carvalho G, Vivet S, Métivier D, Castedo M, Kroemer G. Enrichment of non-synchronized cells in the G1, S and G2 phases of the cell cycle for the study of apoptosis. Biochemical Pharmacology. 72: 1396-404. PMID 16765323 DOI: 10.1016/J.Bcp.2006.04.014 |
0.473 |
|
| 2006 |
Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death and Differentiation. 13: 748-58. PMID 16498458 DOI: 10.1038/Sj.Cdd.4401874 |
0.727 |
|
| 2006 |
Coquelle A, Mouhamad S, Pequignot MO, Braun T, Carvalho G, Vivet S, Métivier D, Castedo M, Kroemer G. Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Cell Death and Differentiation. 13: 873-5. PMID 16498456 DOI: 10.1038/Sj.Cdd.4401881 |
0.437 |
|
| 2006 |
Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, Kiladjian JJ, Ribrag V, Fenaux P, Kroemer G. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 107: 1156-65. PMID 16223780 DOI: 10.1182/Blood-2005-05-1989 |
0.602 |
|
| 2005 |
Gonzalez-Polo RA, Carvalho G, Braun T, Decaudin D, Fabre C, Larochette N, Perfettini JL, Djavaheri-Mergny M, Youlyouz-Marfak I, Codogno P, Raphael M, Feuillard J, Kroemer G. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene. 24: 7503-13. PMID 16091749 DOI: 10.1038/Sj.Onc.1208907 |
0.771 |
|
| 2005 |
Braun T, Carvalho G, Vozenin M, Kiladjian J, Hirsch F, Fenaux P, Kroemer G. P-45 NF-κB is a potential therapeutictarget in high risk MDS: Induction of apoptosis by bortezomib and BAY 11-7082 Leukemia Research. 29: S41. DOI: 10.1016/S0145-2126(05)80109-2 |
0.5 |
|
| Show low-probability matches. |